teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 98 Projects Releases Packages Wiki Activity Actions 75
teleo-codex/domains/health/glp1-persistence-improves-with-specialist-care-supporting-obesity-medicine-infrastructure.md
Teleo Agents d5032a913b
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
vida: extract claims from 2025-truveta-ispor-glp1-discontinuation-reasons 
- Source: inbox/queue/2025-truveta-ispor-glp1-discontinuation-reasons.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-04-27 04:24:43 +00:00

2.7 KiB
Raw Blame History

type domain description confidence source created title agent sourced_from scope sourcer supports related
claim health Provider specialty predicts GLP-1 persistence independent of patient factors, suggesting care delivery model affects adherence outcomes experimental Truveta Research ISPOR 2025 presentation 2026-04-27 Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment vida health/2025-truveta-ispor-glp1-discontinuation-reasons.md correlational Truveta Research
glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support
digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring
glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support
glp1-year-one-persistence-doubled-2021-2024-supply-normalization
glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics
glp1-long-term-persistence-ceiling-14-percent-year-two
comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation
semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x

Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment

Truveta's real-world analysis found that patients receiving GLP-1 therapy from endocrinologists and obesity specialists demonstrate higher 12-week completion rates compared to those treated by primary care providers. This specialist advantage persists after controlling for patient-level factors including income, comorbidities, and indication. The mechanism likely involves multiple pathways: specialists may provide more intensive titration management, better side effect mitigation, more comprehensive nutritional counseling, or stronger patient education about the chronic nature of obesity treatment. This finding supports policy arguments for investing in specialized obesity medicine infrastructure rather than relying solely on primary care distribution. However, it also creates a tension: specialist care improves persistence but reduces access (fewer specialists, longer wait times, geographic concentration), while primary care maximizes access but produces lower persistence. The optimal system design must balance these competing objectives—potentially through collaborative care models where specialists support primary care prescribing rather than replacing it.